The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Baxalta Appeals to IP High Court in Hemlibra Patent Lawsuit against Chugai
Baxalta has filed an appeal with Japan’s Intellectual Property High Court over its claim on patent infringement against Chugai Pharmaceutical’s hemophilia A treatment Hemlibra (emicizumab). Chugai announced on June 29 that it received the complaint. The appeal was filed on…
To read the full story
Related Article
- Japan IP High Court Favors Chugai in Hemlibra Patent Suit
October 4, 2019
- Tokyo Court Strikes Down Baxalta Claim against Hemlibra: Chugai
March 29, 2018
- Baxalta Sues Chugai over Hemophilia A Drug Patent
May 12, 2016
BUSINESS
- Shionogi to Buy Tanabe’s Edaravone Biz for US$2.5 Billion Upfront
December 23, 2025
- Asahi Kasei to Relocate R&D Base to Shonan iPark in January 2027
December 23, 2025
- Daiichi Begins Global PIII of Enhertu in Adjuvant Endometrial Cancer Use
December 23, 2025
- Enhertu Wins US Breakthrough Tag in Post-Neoadjuvant HER2 Breast Cancer
December 23, 2025
- Teikoku to Market Medipost’s Knee OA Cell Therapy in Japan
December 22, 2025
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…